Regulatory press release

CombiGene AB (publ): Nominating committee

The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2024

The 2024 Annual General Meeting resolved that the nominating committee should be appointed as follows: "The nominating committee shall consist of representatives appointed by the three largest owners or jointly registered owner groups as of September 30, 2024, who accept to be part of the nominating committee and the Chairman of the Board. The Chairman of the Board shall be the convener and may participate as an adjunct member but shall not be a member of the nominating committee. If any of the three largest owners should refrain from nominating representatives to the nominating committee, the opportunity shall be passed on to the fourth largest owner, etc. The Chairman of the nominating committee shall be appointed at the first nominating committee meeting. The Chairman shall be the member appointed by the largest shareholder in terms of voting rights, unless the nominating committee unanimously resolves to appoint another member as Chairman of the nominating committee."

The nominating committee has been constituted in accordance with the resolution adopted by the AGM 2024. The nominating committee consists of Jakob Bendtsen representing Strategic Partners A/S (formerly Orphazyme A/S), Jan Nilsson representing Ivar Nordqvist and Lars Thunberg representing M&L Industriförvaltning AB.

The nominating committee’s tasks include submitting proposals to the AGM regarding:

• Chairman of the AGM
• Election of board members
• Chairman of the board of directors
• Remuneration to the board of directors including the chairman
• Election of auditor and remuneration to the auditor
• Rules of procedure for the nominating committee.

Shareholders may submit proposals to the Nominating Committee no later than eight weeks prior to the 2025 Annual General Meeting. Proposals can be sent by e-mail to shareholders@combigene.com or letter to CombiGene AB, Attn: Nominating Committee, c/o Edisen, Skeppsbron 38, SE-111 30 Stockholm, Sweden.

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is Västra Hamnen Corporate Finance AB.

Sign up here to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at combigene.com.